metabolic dysfunction-associated steatohepatitis
metabolic dysfunction-associated steatohepatitis
Explore linked clinical trials. Standard reference: MONDO:000702794 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-10-09 | NCT07288138 | |
| A Study to Assess the Safety, Pharmacokinetics, and Activity of RO7790121 in Participants With Advanced MASH Liver Fibrosis | metabolic dysfunction-associated steatohepatitis | Active, not recruiting | Phase 1 | 2026-10-08 | NCT06903065 | |
| A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis | metabolic dysfunction-associated steatohepatitis | Not yet recruiting | Phase 2 | 2026-10-06 | NCT07859813 | |
| A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 3 | 2026-09-30 | NCT07704892 | |
| A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 3 | 2026-09-30 | NCT07701993 | |
| Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 4 | 2026-09-23 | NCT07718126 | |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 3 | 2026-09-21 | NCT06528314 | |
| Secondary and Tertiary Digital Prevention of Non-alcoholic and Dysmetabolic Liver Disease | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Not stated | 2026-09-17 | NCT06879236 | |
| A Prospective Cohort Study on Patient With Obesity Undergoing Weight Change | Body Weight, Body Weight Changes, Insulin Resistance, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Weight Loss, glucose metabolism disease, hyperinsulinism, metabolic disease, metabolic dysfunction-associated steatohepatitis, nutritional disorder, obesity disorder, overnutrition | Enrolling by invitation | Not stated | 2026-09-15 | NCT07239167 | |
| Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic(PK/PD) Profile of ACT500 in Metabolic Dysfunction-Associated Steatotic Liver Disease(MASLD) | metabolic dysfunction-associated steatohepatitis | Not yet recruiting | Phase 1 | 2026-09-14 | NCT07462455 | |
| Study of Resmetirom in Children and Adolescents With MASH | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, liver disorder, metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 2 | 2026-09-11 | NCT07763015 | |
| ECC4703 Food Effect and Relative Bioavailability Study in Healthy Adult Participants | metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 1 | 2026-09-10 | NCT07334080 | |
| Biometabolic Outcomes After Weight Loss Surgery: An Individualized Approach | Body Weight, Digestive System Diseases, Insulin Resistance, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, fatty liver disease, glucose metabolism disease, hyperinsulinism, liver disorder, metabolic disease, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease, morbid obesity, nutritional disorder, obesity disorder, overnutrition | Enrolling by invitation | Not applicable | 2026-09-10 | NCT04841057 | |
| Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04822181 | |
| Optimizing Noninvasive assessMent Of DysmEtabolic Compensated Advanced Liver Disease | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Not applicable | 2026-09-02 | NCT06888310 | |
| Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants | metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 1 / Phase 2 | 2026-08-27 | NCT07512427 | |
| Detecting Liver Fibrosis in Patients At-risk | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Not yet recruiting | Not stated | 2026-08-20 | NCT07775638 | |
| Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, fatty liver disease, hepatocellular carcinoma, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease, neoplasm | Active, not recruiting | Phase 2 | 2026-08-14 | NCT04550481 | |
| Metabolic Flux Analysis in Metabolic Dysfunction-Associated Steatotic Liver Disease | Body Weight, Digestive System Diseases, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Not applicable | 2026-08-12 | NCT07760909 | |
| Digital Therapy for Fatty Liver Disease | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Not applicable | 2026-08-12 | NCT07007741 | |
| Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES) | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-08-10 | NCT03884075 | |
| Estrogen Administration for the Treatment of NASH in Postmenopausal Women | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Active, not recruiting | Phase 3 | 2026-08-07 | NCT04833140 | |
| A Study of INI-822 in Healthy Volunteers and Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) or Presumed MASH | metabolic dysfunction-associated steatohepatitis | Recruiting | Phase 1 | 2026-08-03 | NCT05945537 | |
| Prospective Cohort and Biobank of Patients With Nonalcoholic Fatty Liver Disease | Digestive System Diseases, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Not stated | 2026-07-21 | NCT07051863 | |
| A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder, metabolic dysfunction-associated steatohepatitis, metabolic dysfunction-associated steatotic liver disease | Recruiting | Phase 2 | 2026-07-08 | NCT06920043 |